Computationally designed GPCR quaternary structures bias signaling pathway activation

Justine S. Paradis, Xiang Feng, Brigitte Murat, Robert E. Jefferson, Badr Sokrat, Martyna Szpakowska, Mireille Hogue, Nick D. Bergkamp, Franziska M. Heydenreich, Martine J. Smit, Andy Chevigné, Michel Bouvier*, Patrick Barth

*Corresponding author for this work

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

Communication across membranes controls critical cellular processes and is achieved by receptors translating extracellular signals into selective cytoplasmic responses. While receptor tertiary structures can be readily characterized, receptor associations into quaternary structures are challenging to study and their implications in signal transduction remain poorly understood. Here, we report a computational approach for predicting receptor self-associations, and designing receptor oligomers with various quaternary structures and signaling properties. Using this approach, we designed chemokine receptor CXCR4 dimers with reprogrammed binding interactions, conformations, and abilities to activate distinct intracellular signaling proteins. In agreement with our predictions, the designed CXCR4s dimerized through distinct conformations and displayed different quaternary structural changes upon activation. Consistent with the active state models, all engineered CXCR4 oligomers activated the G protein Gi, but only specific dimer structures also recruited β-arrestins. Overall, we demonstrate that quaternary structures represent an important unforeseen mechanism of receptor biased signaling and reveal the existence of a bias switch at the dimer interface of several G protein-coupled receptors including CXCR4, mu-Opioid and type-2 Vasopressin receptors that selectively control the activation of G proteins vs β-arrestin-mediated pathways. The approach should prove useful for predicting and designing receptor associations to uncover and reprogram selective cellular signaling functions.

Original languageEnglish
Article number6826
Pages (from-to)1-14
Number of pages14
JournalNature Communications
Volume13
DOIs
Publication statusPublished - 11 Nov 2022

Bibliographical note

Funding Information:
This work was supported by a Swiss National Science Foundation grant (31003A_182263 and 310030_208179), a Novartis Foundation for medical-biological Research grant 21C195, a Swiss Cancer Research grant (KFS-4687-02-2019), a National Institute of Health grant (1R01GM097207), funds from EPFL, and the Ludwig Institute for Cancer Research to P.B., and a grant from the Canadian Institute for health Research (CIHR) (Foundation grant #148431) to M.B. M.J.S. and A.C. were supported by the Luxembourg National Research Fund (Pathfinder “Interceptor” 19/14260467, INTER/FWO “Nanokine” grant 15/10358798, INTER/FNRS grants 20/15084569, and PoC “Megakine” 19/14209621) and F.R.S.-FNRS-Télévie (grants 7.4593.19, 7.4529.19 and 7.8504.20). J.S.P. had studentships from the ‘Groupe de Recherche Universitaire sur le Médicament’ and ‘la Faculté des Études Supérieures et postdoctorales de l’Université de Montréal’. R.E.J. was supported by a Marie Curie Postdoctoral Fellowship and received funding for this project from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 588412. B.S. holds a studentship from the ‘Fond de Recherche du Québec–Santé’ (FRQ-S). B.M. had a fellowship from the ‘Fondation pour la Recherche Médicale (France). M.B. Holds a Canada Research Chair in Signal Transduction and Molecular Pharmacology. The authors thank Dr. Monique Lagacé for her critical reading of the manuscript.

Funding Information:
This work was supported by a Swiss National Science Foundation grant (31003A_182263 and 310030_208179), a Novartis Foundation for medical-biological Research grant 21C195, a Swiss Cancer Research grant (KFS-4687-02-2019), a National Institute of Health grant (1R01GM097207), funds from EPFL, and the Ludwig Institute for Cancer Research to P.B., and a grant from the Canadian Institute for health Research (CIHR) (Foundation grant #148431) to M.B. M.J.S. and A.C. were supported by the Luxembourg National Research Fund (Pathfinder “Interceptor” 19/14260467, INTER/FWO “Nanokine” grant 15/10358798, INTER/FNRS grants 20/15084569, and PoC “Megakine” 19/14209621) and F.R.S.-FNRS-Télévie (grants 7.4593.19, 7.4529.19 and 7.8504.20). J.S.P. had studentships from the ‘Groupe de Recherche Universitaire sur le Médicament’ and ‘la Faculté des Études Supérieures et postdoctorales de l’Université de Montréal’. R.E.J. was supported by a Marie Curie Postdoctoral Fellowship and received funding for this project from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 588412. B.S. holds a studentship from the ‘Fond de Recherche du Québec–Santé’ (FRQ-S). B.M. had a fellowship from the ‘Fondation pour la Recherche Médicale (France). M.B. Holds a Canada Research Chair in Signal Transduction and Molecular Pharmacology. The authors thank Dr. Monique Lagacé for her critical reading of the manuscript.

Publisher Copyright:
© 2022, The Author(s).

Funding

This work was supported by a Swiss National Science Foundation grant (31003A_182263 and 310030_208179), a Novartis Foundation for medical-biological Research grant 21C195, a Swiss Cancer Research grant (KFS-4687-02-2019), a National Institute of Health grant (1R01GM097207), funds from EPFL, and the Ludwig Institute for Cancer Research to P.B., and a grant from the Canadian Institute for health Research (CIHR) (Foundation grant #148431) to M.B. M.J.S. and A.C. were supported by the Luxembourg National Research Fund (Pathfinder “Interceptor” 19/14260467, INTER/FWO “Nanokine” grant 15/10358798, INTER/FNRS grants 20/15084569, and PoC “Megakine” 19/14209621) and F.R.S.-FNRS-Télévie (grants 7.4593.19, 7.4529.19 and 7.8504.20). J.S.P. had studentships from the ‘Groupe de Recherche Universitaire sur le Médicament’ and ‘la Faculté des Études Supérieures et postdoctorales de l’Université de Montréal’. R.E.J. was supported by a Marie Curie Postdoctoral Fellowship and received funding for this project from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 588412. B.S. holds a studentship from the ‘Fond de Recherche du Québec–Santé’ (FRQ-S). B.M. had a fellowship from the ‘Fondation pour la Recherche Médicale (France). M.B. Holds a Canada Research Chair in Signal Transduction and Molecular Pharmacology. The authors thank Dr. Monique Lagacé for her critical reading of the manuscript. This work was supported by a Swiss National Science Foundation grant (31003A_182263 and 310030_208179), a Novartis Foundation for medical-biological Research grant 21C195, a Swiss Cancer Research grant (KFS-4687-02-2019), a National Institute of Health grant (1R01GM097207), funds from EPFL, and the Ludwig Institute for Cancer Research to P.B., and a grant from the Canadian Institute for health Research (CIHR) (Foundation grant #148431) to M.B. M.J.S. and A.C. were supported by the Luxembourg National Research Fund (Pathfinder “Interceptor” 19/14260467, INTER/FWO “Nanokine” grant 15/10358798, INTER/FNRS grants 20/15084569, and PoC “Megakine” 19/14209621) and F.R.S.-FNRS-Télévie (grants 7.4593.19, 7.4529.19 and 7.8504.20). J.S.P. had studentships from the ‘Groupe de Recherche Universitaire sur le Médicament’ and ‘la Faculté des Études Supérieures et postdoctorales de l’Université de Montréal’. R.E.J. was supported by a Marie Curie Postdoctoral Fellowship and received funding for this project from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 588412. B.S. holds a studentship from the ‘Fond de Recherche du Québec–Santé’ (FRQ-S). B.M. had a fellowship from the ‘Fondation pour la Recherche Médicale (France). M.B. Holds a Canada Research Chair in Signal Transduction and Molecular Pharmacology. The authors thank Dr. Monique Lagacé for her critical reading of the manuscript.

FundersFunder number
F.R.S.-FNRS-Télévie7.8504.20, 7.4593.19, 7.4529.19
Groupe de Recherche Universitaire sur le Médicament
INTER
National Institutes of Health
National Institute of General Medical SciencesR01GM097207
Novartis Foundation21C195
Ludwig Institute for Cancer Research
Horizon 2020 Framework Programme
H2020 Marie Skłodowska-Curie Actions588412
Canadian Institutes of Health Research148431
Fonds de Recherche du Québec - Santé
École Polytechnique Fédérale de Lausanne
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung310030_208179, 31003A_182263
Fonds National de la Recherche Luxembourg19/14260467
Fonds De La Recherche Scientifique - FNRS19/14209621, 20/15084569
Fondation pour la Recherche Médicale
Fonds Wetenschappelijk Onderzoek15/10358798
Swiss Cancer Research FoundationKFS-4687-02-2019
‘la Faculté des Études Supérieures et postdoctorales de l’Université de Montréal

    Fingerprint

    Dive into the research topics of 'Computationally designed GPCR quaternary structures bias signaling pathway activation'. Together they form a unique fingerprint.

    Cite this